Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) affects more than a third of the global adult population, yet early-stage disease often goes undetected. Ultrasound is the most accessible liver imaging modality, but conventional systems frequently lack the sensitivity needed to reveal subtle echogenic changes - particularly in patients with obesity, where image quality is degraded.

ContextVision addresses this diagnostic gap with a new image-processing innovation; a dedicated MASLD ultrasound preset designed to deliver clearer, more reliable liver visualization. Built on a novel multi-scale architecture, the technology enhances both large-scale organ contrast and fine-scale parenchymal detail. Clinicians gain sharper definition of structures such as portal vein walls and the diaphragm, as well as improved contrast between the liver and kidney - key indicators for early steatosis assessment.

The MASLD preset fits seamlessly into routine workflows and can be integrated as a customizable feature on existing ultrasound systems. Radiologists note that it strengthens confidence in subtle findings, supports consensus across teams, and offers a more standardized visual reference.
“I would use this feature to reinforce clinical suspicions and build alignment among colleagues,” says Jesper Danielson, Senior Radiologist at Capio S:t Göran Hospital, Stockholm, Sweden.

By elevating diagnostic clarity and supporting streamlined collaboration, ContextVision advances a practical, near-patient solution for MASLD evaluation.

ContextVision – See More, Know More
For more information, visit contextvision.com.

Products and Clearances Homepage